Decline in Upfront License Fees and Royalty Income
First written in FY2017-Q3. 13 of 30 entries say "Worsened", first in FY2019-Q1. Latest entry: FY2026.
KYORIN Pharmaceutical moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Overseas sales of new pharmaceuticals declined due to the reactionary drop in contractual upfront-payment income, falling to ¥693 million, down 92.2% from the previous fiscal year.」
Overseas new-pharmaceutical sales fell 92.2% from the previous fiscal year due to the reactionary decline in the contractual upfront payment received for licensing KRP-M223 in the previous fiscal year. - FY2026-H1MitigatedAnnual report
「As income and other items related to gatifloxacin were recorded during the interim consolidated accounting period, overseas sales of new pharmaceuticals were ¥504 million, up 18.8% year on year.」
Overseas new-pharmaceutical income rose 18.8% year on year due to income and other items related to gatifloxacin, improving from the previous declining trend. - FY2025MitigatedAnnual report
「In addition to temporary income related to gatifloxacin, a contractual upfront payment received in connection with the licensing of a compound originated by the company to Novartis (headquartered in Switzerland) was recorded, resulting in overseas new-pharmaceutical sales of ¥8,860 million, up 2,195.2% from the previous fiscal year.」
Overseas new-pharmaceutical income rose 2,195.2% from the previous fiscal year due to temporary income from gatifloxacin and the contractual upfront payment for licensing KRP-M223. However, the disclosure also indicates dependence on temporary income. - FY2025-H1MitigatedAnnual report
「As temporary income related to gatifloxacin was recorded during the interim consolidated accounting period, overseas sales of new pharmaceuticals were ¥424 million, up 153.8% year on year.」
Overseas new-pharmaceutical sales rose 153.8% year on year due to temporary income related to gatifloxacin. However, the income is described as temporary. - FY2024MitigatedAnnual report
「Overseas sales of new pharmaceuticals were ¥386 million, up 25.1% from the previous fiscal year.」
Overseas new-pharmaceutical sales turned upward from the decline through the previous year-on-year period, reaching ¥386 million, up 25.1% from the previous fiscal year. - FY2024-Q3MitigatedAnnual report
「Overseas sales of new pharmaceuticals were ¥291 million, down 45.3% year on year.」
The decline in overseas new-pharmaceutical sales continued, although the rate of decline narrowed slightly to 45.3% from 46.5% year on year in the previous quarter. - FY2024-Q2WorsenedAnnual report
「Revenue from new drugs (overseas) was ¥167 million, down 46.5% year on year.」
Overseas new-drug revenue was ¥167 million, down 46.5% year on year, as the decline continued in overseas income dependent on license fees, royalties and other sources. - FY2024-Q1WorsenedAnnual report
「Revenue from new drugs (overseas) was ¥55 million, down 61.4% year on year.」
Overseas new-drug revenue was ¥55 million, down 61.4% year on year, as the decline continued in overseas income dependent on license fees, royalties and other sources. - FY2023WorsenedAnnual report
「Due mainly to a decline from the previous fiscal year's upfront fee income under contracts related to product licensing, revenue was ¥308 million, down 70.1% from the previous fiscal year.」
Overseas new-drug income fell 70.1% from the previous fiscal year, due mainly to a decline from the previous fiscal year's upfront fees under licensing agreements. - FY2023-Q2MitigatedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) fell below the year-earlier period, resulting in revenue of ¥312 million, down 8.6% year on year.」
Although gatifloxacin-related income fell below the year-earlier period, the decline in the cumulative period through the current quarter narrowed to 8.6% year on year from the 28.9% year-on-year decline previously reported. - FY2023-Q1WorsenedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) fell below the year-earlier period, resulting in revenue of ¥142 million, down 28.9% year on year.」
For overseas new-drug income, gatifloxacin-related income fell below the year-earlier period, and revenue decreased 28.9% year on year. - FY2022-Q2Revenue decline due to a decline from transfer incomeAnnual report
「Although gatifloxacin sales increased, revenue declined from the previous fiscal year to ¥342 million, compared with ¥527 million in the year-earlier period, due to a decline from the previous fiscal year's revenue from the transfer of intellectual property and other assets related to the immunomodulator KRP-203 to Priothera, headquartered in Ireland.」
Although gatifloxacin-related income increased, overseas new-drug revenue fell below the year-earlier period due to a decline from the previous fiscal year's transfer income related to KRP-203 intellectual property and other assets. - FY2022-Q1WorsenedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) fell below the previous year, resulting in revenue of ¥200 million, compared with ¥220 million in the year-earlier period.」
Gatifloxacin-related income fell below the year-earlier period, and overseas new-drug revenue declined. The license agreement for the product also expired and ended during the quarter. - FY2021-Q3WorsenedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) fell below the previous year, while lower upfront fee income under license agreements and other factors resulted in revenue of ¥755 million, down 38.3% year on year.」
Due to lower gatifloxacin-related income and upfront fee income under license agreements, overseas new-drug revenue fell 38.3% year on year. - FY2021-Q2Declining factors and increase from transfer incomeAnnual report
「Although income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) fell below the previous year, the transfer of intellectual property and other assets related to the immunomodulator KRP-203 to Priothera, headquartered in Ireland, contributed to revenue of ¥527 million, up 35.1% year on year.」
Although gatifloxacin-related income declined, the transfer of intellectual property and other assets related to KRP-203 contributed, and overseas new-drug revenue increased 35.1% year on year. - FY2021-Q1WorsenedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) fell below the previous year, resulting in revenue of ¥220 million, down 41.5% year on year.」
Overseas new-drug income, which had increased through the previous quarter, declined as gatifloxacin-related income fell below the previous year, and revenue decreased 41.5% year on year. - FY2020-Q3MitigatedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) exceeded the previous year. In addition, upfront fee income and other income from the license agreement for the overactive bladder treatment vibegron signed with South Korea's Jeil also contributed to revenue, which was ¥1,224 million, up 94.5% year on year.」
In addition to higher gatifloxacin-related income, upfront license fee income and other income from vibegron contributed, and overseas new-drug revenue increased 94.5% year on year. - FY2020-Q1MitigatedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) exceeded the previous year, resulting in revenue of ¥376 million, up 157.3% year on year.」
Gatifloxacin-related income exceeded the previous year, and overseas new-drug revenue increased 157.3% year on year. - FY2019WorsenedAnnual report
「Due mainly to a decline from the previous fiscal year's upfront fee income associated with progress in the development of the FPR2 agonist program (licensed to U.S.-based Bristol-Myers Squibb), revenue decreased by ¥2,509 million from the previous fiscal year to ¥830 million, down 75.1% year on year.」
Due mainly to a decline from the previous fiscal year's upfront fee income from the FPR2 agonist program, overseas new-drug revenue fell 75.1% year on year. - FY2019-Q3WorsenedAnnual report
「Due mainly to a decline from the previous fiscal year's upfront fee income associated with progress in the development of the FPR2 agonist program (licensed to U.S.-based Bristol-Myers Squibb), revenue decreased by ¥2,475 million from the year-earlier period to ¥629 million, down 79.7% year on year.」
Due mainly to a decline from the previous fiscal year's upfront fee income related to the FPR2 agonist program, overseas new-drug revenue fell 79.7% year on year. - FY2019-Q2MitigatedAnnual report
「As income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) exceeded the previous year, revenue was ¥604 million, up 15.5% year on year.」
Gatifloxacin-related income, which had been cited as a negative factor through the previous quarter, exceeded the previous year, and overseas new-drug revenue increased 15.5% year on year. - FY2019-Q1WorsenedAnnual report
「At Kyorin Pharmaceutical Co., Ltd., income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) fell below the previous year, resulting in revenue of ¥146 million, down 39.7% year on year.」
Gatifloxacin-related income, which had recovered in the previous fiscal year, declined 39.7% year on year. - FY2018RestatedAnnual report
「Upfront fee income associated with progress in the development of the FPR2 agonist program (licensed to U.S.-based Bristol-Myers Squibb) was recognized, and income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) also exceeded the previous year.」
The recovery in license-related income, driven by upfront fee income from the FPR2 agonist and higher gatifloxacin-related income, was confirmed in the full-year results. - FY2018-Q3MitigatedAnnual report
「Upfront license fee income associated with progress in the development of the FPR2 agonist program (licensed to U.S.-based Bristol-Myers Squibb) was recognized, and income related to the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan) also exceeded the previous year. As a result, revenue was ¥3,104 million, up 969.3% year on year.」
License-related income, which had been cited as a negative factor through the previous year, increased as a result of upfront fee income from the FPR2 agonist program and higher gatifloxacin-related income, and overseas new-drug revenue rose 969.3% year on year. - FY2018-Q2RestatedAnnual report
「Due to higher royalty income from the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan), revenue was ¥523 million, up 52.5% year on year.」
Royalty income from gatifloxacin, which had been a negative factor through the previous year, increased 52.5% year on year in the cumulative second-quarter period. - FY2018-Q1MitigatedAnnual report
「Due to higher royalty income from the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan), revenue was ¥242 million, up 278.3% year on year.」
Royalty income from gatifloxacin, which had been cited as a negative factor through the previous year, increased 278.3% year on year in the current quarter. - FY2017RestatedAnnual report
「Due to a decline from the year-earlier upfront license fee income recognized in December under the license agreement with U.S.-based Bristol-Myers Squibb, as well as lower royalty income from the broad-spectrum antibacterial ophthalmic drug gatifloxacin (licensed to U.S.-based Allergan), revenue was ¥764 million, down 86.3% year on year.」
The decline from the previous year's upfront license fee income and lower royalty income continue to be cited as factors in the full-year results. - FY2017-Q3MaterialisedAnnual report
「Revenue was ¥290 million, down 94.3% year on year, due to the decline following the upfront license fee recorded in December of the previous year under the license agreement with Bristol-Myers Squibb in the United States, as well as lower royalty income from the broad-spectrum antibacterial ophthalmic product gatifloxacin, licensed to Allergan in the United States.」
The decline in upfront license-fee income following the prior-year recognition and lower royalty income actually occurred, resulting in a 94.3% year-on-year decline in overseas new drug sales.